Invesco Pharmaceuticals ETF (PJP)

Key Metrics

TER 0.57% per year

Distribution policy Distributing

Fund size USD 333 M

Inception date June 23, 2005

Holdings 34

Fund currency USD

Fund domicile US

Provider Invesco

For full official fund details, factsheets, and holdings, visit invesco.com (opens in new tab).

Historical Return

Last updated: Aug 01, 2026

1 Year +47.5% +0.9% Div

3 Years (avg.) +16.2% +0.9% Div

5 Years (avg.) +8.3% +0.9% Div

Risk & Analysis Metrics

Last updated: Aug 01, 2026

Volatility

15.74% 1 Year

15.64% 3 Years

16.06% 5 Years

18.23% 10 Years

Max Drawdown

-9.67% 1 Year

-17.00% 3 Years

-18.74% 5 Years

-35.20% 10 Years

Sharpe Ratio

2.02 1 Year

0.72 3 Years

0.30 5 Years

0.17 10 Years

Return Triangle (Heatmap)

Last updated: Aug 01, 2026

	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
2011	20.5%	21.0%	30.7%	29.2%	24.0%	15.7%	15.2%	12.5%	11.5%	11.3%	11.5%	10.2%	9.1%	9.0%	10.1%
2012		21.5%	36.1%	32.3%	24.9%	14.8%	14.3%	11.4%	10.4%	10.4%	10.6%	9.3%	8.2%	8.2%	9.4%
2013			52.5%	38.0%	26.0%	13.2%	13.0%	9.8%	8.9%	9.0%	9.5%	8.2%	7.1%	7.2%	8.5%
2014				24.8%	14.5%	2.5%	4.8%	2.8%	2.9%	3.9%	5.1%	4.1%	3.4%	3.8%	5.5%
2015					5.0%	-7.2%	-1.1%	-2.1%	-1.0%	0.8%	2.5%	1.8%	1.2%	1.9%	3.9%
2016						-17.9%	-4.1%	-4.4%	-2.4%	0.0%	2.1%	1.4%	0.8%	1.6%	3.8%
2017							12.1%	3.2%	3.4%	5.0%	6.6%	5.0%	3.8%	4.3%	6.5%
2018								-4.9%	-0.7%	2.8%	5.3%	3.6%	2.4%	3.2%	5.8%
2019									3.6%	6.9%	9.0%	5.9%	4.0%	4.6%	7.5%
2020										10.3%	11.8%	6.6%	4.1%	4.9%	8.1%
2021											13.3%	4.9%	2.1%	3.5%	7.7%
2022												-2.9%	-3.1%	0.5%	6.3%
2023													-3.3%	2.2%	9.6%
2024														8.1%	16.7%
2025															26.0%

Distributions

*by ETF Portfolio Weight Last updated: Aug 01, 2026

Profit Margin Distribution

< 0%

18%

1y 3y N/A N/A

0 - 5%

1y 3y N/A N/A

5 - 10%

12%

1y 3y N/A N/A

10 - 15%

20%

1y 3y N/A N/A

15 - 20%

1y 3y N/A N/A

20 - 30%

16%

1y 3y N/A N/A

30 - 40%

10%

1y 3y N/A N/A

> 40%

10%

1y 3y N/A N/A

P/E Ratio Distribution

< 0

18%

1y 3y N/A N/A

0 - 10

1y 3y N/A N/A

10 - 15

11%

1y 3y N/A N/A

15 - 20

20%

1y 3y N/A N/A

20 - 25

1y 3y N/A N/A

25 - 35

14%

1y 3y N/A N/A

35 - 50

19%

1y 3y N/A N/A

> 50

16%

1y 3y N/A N/A

Discounted Cash Flow

Weighted Average Undervaluation

N/A

Undervalued

> 60%

1y 3y N/A N/A

45 - 60%

1y 3y N/A N/A

30 - 45%

1y 3y N/A N/A

15 - 30%

1y 3y N/A N/A

Fair (±15%)

1y 3y N/A N/A

Overvalued

15 - 30%

1y 3y N/A N/A

30 - 45%

1y 3y N/A N/A

45 - 60%

1y 3y N/A N/A

> 60%

1y 3y N/A N/A

Market Cap Size Distribution

Micro Cap

0.0%

1y 3y N/A N/A

Small Cap

15.8%

1y 3y N/A N/A

Mid Cap

24.3%

1y 3y N/A N/A

Large Cap

35.9%

1y 3y N/A N/A

Mega Cap

24.0%

1y 3y N/A N/A

Micro: < $300M Small: $300M–$2B Mid: $2B–$10B Large: $10B–$200B Mega: > $200B

Average metrics of all companies in portfolio

Last updated: Aug 02, 2026

Market
Average

Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares.	$137B	-
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price.	1.43%	2.01%
Beta Indicates the relationship between the price performance of a share and the market.	0.55	-
P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth.	35.91	30.76
Negative P/E Ratio a negative P/E ratio shows that the company is not profitable, and it shows how many years it would take the company to lose its entire market capitalisation if it did not change anything	-85.69	-
Profitable Companies	73%	-
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued.	807.33	9.33
Price to Sales Ratio Market cap divided by the revenue in the most recent year.	5.27	7.93
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company	9.21	10.19

Market
Average

Enterprise Value to EBIT Enterprise Value divided by EBIT	25.49	18.56
Enterprise Value to Revenue Enterprise value divided by revenue	69.09	7.93
Total Debt to Enterprise Value Total debt divided by enterprise value	0.19	0.04
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary.	0.48	0.29
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability.	-1218.27%	21.90%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago.	-	-116.0%
Return on Equity Equity divided by market cap.	21.71%	2.81%
Return on Assets Indicates a company's profitability in relation to its total assets.	4.34%	4.15%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits.	9.85%	3.82%

Sectors

Manufacturing	97.6%
Finance and Insurance	2.7%

Countries

United States	94.7%
Ireland	5.3%
Other	0.0%

Limit holdings to companies in a single sector.

$0B >$1T

Ratio between share price and earnings per share. A low ratio could indicate undervaluation.

<0 >50

Ratio of dividends in the last 12 months to current share price.

0% 3%

Revenue increase compared to the same quarter one year ago.

0% 30%

Net income increase compared to the same quarter one year ago.

0% 30%

Profitability of the last quarter.

<-30% >30%

A higher ratio indicates a higher risk. The ratio is difficult to compare between industries.

<0 >3

Discounted cash flow valuation vs. current price. Positive = undervalued, negative = overvalued.

<-50% >+100%

Market Cap

P/E Ratio

Total Investment

Weight

Pfizer Inc.

PFE - Manufacturing

Market Cap $142.54B

P/E Ratio 19.1

Dividends 6.9%

Total Investment $17.37M

Weight 5.21%

Loading details…

Johnson & Johnson

JNJ - Manufacturing

Market Cap $617.78B

P/E Ratio 29.6

Dividends 2.0%

Total Investment $16.48M

Weight 4.95%

Loading details…

Abbvie Inc

ABBV - Manufacturing

Market Cap $443.24B

P/E Ratio 123.0

Dividends 2.7%

Total Investment $16.33M

Weight 4.90%

Loading details…

AMGEN Inc.

AMGN - Manufacturing

Market Cap $207.87B

P/E Ratio 26.6

Dividends 2.5%

Total Investment $15.96M

Weight 4.79%

Loading details…

Lilly(Eli) & Co

LLY - Manufacturing

Market Cap $1.08T

P/E Ratio 40.7

Dividends 0.6%

Total Investment $15.85M

Weight 4.76%

Loading details…

Gilead Sciences, Inc.

GILD - Manufacturing

Market Cap $161.66B

P/E Ratio 17.5

Dividends 2.5%

Total Investment $15.64M

Weight 4.70%

Loading details…

Merck & Co Inc

MRK - Manufacturing

Market Cap $321.62B

P/E Ratio 36.6

Dividends 2.6%

Total Investment $15.55M

Weight 4.67%

Loading details…

Abbott Laboratories

ABT - Manufacturing

Market Cap $184.11B

P/E Ratio 34.0

Dividends 2.3%

Total Investment $13.99M

Weight 4.20%

Loading details…

Travere Therapeutics Inc

TVTX - Manufacturing

Market Cap $5.2B

P/E Ratio -114.1

Dividends 0.0%

Total Investment $13.33M

Weight 4.00%

Loading details…

Corcept Therapeutics Inc

CORT - Manufacturing

Market Cap $12.38B

P/E Ratio 220.2

Dividends 0.0%

Total Investment $12.47M

Weight 3.74%

Loading details…

Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

LGND - Manufacturing

Market Cap $5.76B

P/E Ratio 36.7

Dividends 0.0%

Total Investment $11.86M

Weight 3.56%

Loading details…

United Therapeutics Corp

UTHR - Manufacturing

Market Cap $21.98B

P/E Ratio 17.7

Dividends 0.0%

Total Investment $11.8M

Weight 3.54%

Loading details…

Liquidia Corp

LQDA - Manufacturing

Market Cap $7.48B

P/E Ratio 351.8

Dividends 0.0%

Total Investment $11.42M

Weight 3.43%

Loading details…

Jazz Pharmaceuticals plc

JAZZ - Manufacturing

Market Cap $15.88B

P/E Ratio 616.7

Dividends 0.0%

Total Investment $11.42M

Weight 3.43%

Loading details…

Harmony Biosciences Holdings Inc

HRMY - Manufacturing

Market Cap $2.04B

P/E Ratio 14.0

Dividends 0.0%

Total Investment $10.84M

Weight 3.25%

Loading details…

Ocular Therapeutix Inc

OCUL - Manufacturing

Market Cap $1.79B

P/E Ratio -5.6

Dividends 0.0%

Total Investment $10.23M

Weight 3.07%

Loading details…

ANI Pharmaceuticals Inc

ANIP - Manufacturing

Market Cap $1.8B

P/E Ratio 19.3

Dividends 0.0%

Total Investment $10.13M

Weight 3.04%

Loading details…

Bristol-Myers Squibb Co.

BMY - Manufacturing

Market Cap $133.37B

P/E Ratio 14.4

Dividends 3.8%

Total Investment $9.62M

Weight 2.89%

Loading details…

Innoviva Inc

INVA - Manufacturing

Market Cap $1.55B

P/E Ratio 3.0

Dividends 0.0%

Total Investment $9.6M

Weight 2.88%

Loading details…

Biogen Inc

BIIB - Manufacturing

Market Cap $29.99B

P/E Ratio 35.7

Dividends 0.0%

Total Investment $9.48M

Weight 2.85%

Loading details…

Key Metrics

Compare similar ETFs

Historical Return

Risk & Analysis Metrics

Volatility

Max Drawdown

Sharpe Ratio

Return Triangle (Heatmap)

Distributions

Profit Margin Distribution

P/E Ratio Distribution

Discounted Cash Flow

Market Cap Size Distribution

Portfolio Concentration

Latest News

Why AbbVie Stock Slumped Today

AbbVie Inc. (ABBV) Q2 2026 Earnings Call Transcript

AbbVie Inc (ABBV) (Q2 2026) Earnings Call Highlights: Robust Growth Driven by Skyrizi and Rinvoq, Pipeline Advances

Average metrics of all companies in portfolio

Sectors

Countries

Stock Screener

Pfizer Inc.

Pfizer Inc.

Johnson & Johnson

Johnson & Johnson

Abbvie Inc

Abbvie Inc

AMGEN Inc.

AMGEN Inc.

Lilly(Eli) & Co

Lilly(Eli) & Co

Gilead Sciences, Inc.

Gilead Sciences, Inc.

Merck & Co Inc

Merck & Co Inc

Abbott Laboratories

Abbott Laboratories

Travere Therapeutics Inc

Travere Therapeutics Inc

Corcept Therapeutics Inc

Corcept Therapeutics Inc

Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B

United Therapeutics Corp

United Therapeutics Corp

Liquidia Corp

Liquidia Corp

Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc

Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Ocular Therapeutix Inc

Ocular Therapeutix Inc

ANI Pharmaceuticals Inc

ANI Pharmaceuticals Inc

Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Innoviva Inc

Innoviva Inc

Biogen Inc

Biogen Inc

Cookie Settings